A Phase 1 interventional study of ONO-4578 and ONO-4538 in Colorectal Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Colorectal Neoplasms with a site in Japan — 38 open to participants now, 67 under way, 14 of them phase 3. Colorectal Neoplasms · Japan.
Among the 174 studies in Colorectal Neoplasms with a site in Japan, this one is the 136th largest by enrollment of the 160 interventional ones that give a count, is one of 15 that started in 2021, is one of 41 in phase 1, reaches primary completion later than 27 of the 66 other live ones, and was the 144th registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →38 of the 174 studies in Colorectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan, Denmark
Ages 18+
AbbVie · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Japan, United States, Argentina and 16 more countries
Ages 18+
Incyte Corporation · Sites in Japan, United States, Argentina and 19 more countries
Ages 18+
Boston Scientific Corporation · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 67 · Phase 3 49
First in 1996; this study’s year is marked. 15 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 198 across the 160 interventional studies, 772 across the 14 observational. Of the 96 that completed or were terminated, 46 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 174 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Colorectal Neoplasms with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06179160Incyte CorporationA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 2027-01-01 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT06853496Eiji ShinozakiStudy of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer | 2027-03 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 174 studies in Colorectal Neoplasms with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-4578 · Drug: ONO-4538 · Drug: Capecitabine · Drug: Oxaliplatin · Drug: Bevacizumab
Drug: ONO-4578 · Drug: ONO-4538 · Drug: Oxaliplatin · Drug: Fluorouracil · Drug: Calcium Levofolinate Hydrateb · Drug: Bevacizumab
Specified dose on specified days
Specified dose on specified days
Also known as: Nivolumab
Specified dose on specified days
Also known as: XELODA
Specified dose on specified days
Also known as: ELPLAT
Specified dose on specified days
Also known as: 5-FU
Specified dose on specified days
Also known as: ISOVORIN
Specified dose on specified days
Also known as: AVASTIN
Incidence and severity of AEs and SAEs
Time frame: up to 3years
Incidence and severity of clinical laboratory abnormalities
Time frame: up to 3years
12-lead electrocardiography (Heart rate)
Time frame: up to 3years
12-lead electrocardiography (PR interval)
Time frame: up to 3years
12-lead electrocardiography (RR interval)
Time frame: up to 3years
12-lead electrocardiography (QRS width)
Time frame: up to 3years
12-lead electrocardiography (QT interval)
Time frame: up to 3years
Chest X-ray test
Time frame: up to 3years
ECOG performance status
Time frame: up to 3years
Objective response rate (ORR)
Time frame: up to 3years
Disease control rate (DCR)
Time frame: up to 3years
Overall survival (OS)
Time frame: up to 3years
Progression-free survival (PFS)
Time frame: up to 3years
Duration of response (DOR)
Time frame: up to 3years
Time to response (TTR)
Time frame: up to 3years
Best oveall response (BOR)
Time frame: up to 3years
Percentage of change in the sum of tumor diameters of target lesions
Time frame: up to 3years
Maximum percent change in the sum diameters of the target lesions
Time frame: up to 3years
Time course of tumor markers
Time frame: up to 3years
Plasma ONO-4578 concentration
Time frame: up to 3years
Serum ONO-4538 concentration
Time frame: up to 3years
Anti-ONO-4538 antibody
Time frame: up to 3years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Oct 2027, 81 months after the start.
Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 81 months is above that.
Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ono Pharmaceutical Co., Ltd. →